| 1. |
中华医学会呼吸病学分会慢性阻塞性肺疾病. 慢性阻塞性肺疾病诊疗指南(2007年修订版)[J]. 中华结核和呼吸杂志, 2007, 30(1): 8-17.
|
| 2. |
Gan WQ, Man SF, Senthilselvan A, et al. Associasion between chronic obstructive pulmonary disease and systemic inflammation:a systematic review and a meta-analysis[J]. Thorax, 2004, 59(7): 574-580.
|
| 3. |
Garrod R, Marshall J, Barley E, et al.The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD) [J]. Prim Care Respir J, 2007, 16(4): 236-240.
|
| 4. |
Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxyl-methylglutaryl cocenzyme a reductase in pulmonary inflammation and host defense[J]. Am J Respir Crit Care Med, 2005, 171(6): 606-615.
|
| 5. |
丁艳苓, 姚婉贞. 慢性阻塞性肺疾病与哮喘气道炎症的研究[J]. 中国呼吸与危重监护杂志, 2004, 3(6): 410-412, 415.
|
| 6. |
Ou XM, Wang BD, Wen FQ, et al. Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats[J]. Chin Med J (Engl), 2008, 121(17): 1680-1687.
|
| 7. |
Ghavami S, Mutawe MM, Hauff K, et al. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome[J]. Biochim Biophys Acta, 2010, 1803(4): 452-467.
|
| 8. |
Hothersall E, McSharry C, Tomo NC. Potential therapeutic role for statins in respiratory disease[J]. Thorox, 2006, 61(8): 729-734.
|
| 9. |
Morimoto K, Janseen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease[J]. J Immunol, 2006, 176(12): 7657-7665.
|
| 10. |
Kim DY, Ryu SY, Lim JE, et al. Anti-inflammatory mechanism of simvastin in mouse allergic asthma model[J]. Eur J Pharmacol, 2007, 557(1): 76-86.
|
| 11. |
Cheelo M, Anselmi A, Spadaccio C, et al. simvastin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery[J]. Ann Thorac Surg, 2007, 83(4): 1374-1380.
|
| 12. |
Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin[J]. Am J Cardiol, 2008, 101(4): 530-535.
|
| 13. |
Kedissi JI, Younis WG, Chbier EA, et al. The use of statins and lung function incurrent and former smokers[J]. Chest, 2007, 132(6): 1764-1767.
|
| 14. |
Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function:VA Normative Aging Study[J]. Am J Respir Crit Care Med, 2007, 176(8): 742-747.
|
| 15. |
夏书月, 康健, 何巍, 等. 辛伐他汀对COPD急性加重期患者诱导痰血管内皮生长因子水平和肺功能的影响[J]. 中国呼吸与危重监护杂志, 2010, 9(3): 295-297.
|
| 16. |
Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal preliferation and pulmonary hypertension in rats[J]. Am J Respir Crit Care Med, 2002, 166(10): 1403-1408.
|
| 17. |
Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J]. Circulation, 2003, 108(13): 1640-1645.
|
| 18. |
Syseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD[J]. Eur Respir J, 2007, 29(2): 279-283.
|
| 19. |
van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on comparison of those with versus without associated chronic obstructive pulmonary disease[J]. Am J Cardiol, 2008, 102(2): 192-196.
|
| 20. |
Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins,angiotensin-converting enzyme inhibitors,and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease[J]. J Am Coll Cardiol, 2006, 47(12): 2544-2560.
|
| 21. |
Phillips MI, Kagiyama S. Angiotensin I as a proinflammatory mediator[J]. Curr Opin lnvestig Drugs, 2002, 3(4): 569-577.
|
| 22. |
Suzuki Y, Ruiz-Ortega M, Lorenzo O, et a1. Inflammation and angiotensinⅡ[J]. Int J Biochem Cell Biol, 2003, 35(6): 881-900.
|
| 23. |
Ruiz-Ortega M, Lorenzo O, Suzuki Y, et a1. Prolnflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens, 2001, 10(3): 321-329.
|
| 24. |
Elferink JG, de Koster BM. The stimulation of human neutrophil migration by angiotensin I: its dependence on Caand the involvement of cyclic GMP[J]. Br J Pharmacol, 1997, 121(4): 643-648.
|
| 25. |
Raiden S, Nahmod K, Namod V, et a1. Nonpeptide antagonists of AT1 receptor for angiotensin Ⅱ delay the onset of acute respiratory distress syndrome[J]. J Pharmacol Exp Ther, 2002, 303(1): 45-51.
|
| 26. |
Hernández-Presa MA, Bustos C, Ortego M, et a1. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent prolnflammatory factors but not of collagenI in a rabbit model of atherosclerosis[J]. Am J Pathol, 1998, 153(6): 1825-1837.
|
| 27. |
Gräfe M, Auch-Schwelk W, Zakrzewicz A, et a1. AngiotensinⅡ-induced leukocytes adhesion on human coronary endothelial cells is mediated by E-selection[J]. Circ Res, 1997, 81(5): 804-811.
|
| 28. |
Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis[J]．Ann Intern Med，2001, 134(5): 426-427．.
|
| 29. |
Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative efect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hyperholesterolemic and hypertensive patients[J]. J Cardiovasc Pharmacol, 2002, 40(1): 28-34.
|
| 30. |
Horiuchi M, Cui TX, Li Z, et a1. Fluvastatin enhances the inhibit-tory effects of a selective angiotensinⅡ Type 1 receptor blocker Valsartan On vascular neointimal formation[J]. Circulation, 2003, 107(1): 106-112.
|
| 31. |
Wassmann S, Laufs U, Bäumer AT, et a1. Inhibition of geranylgeranylation reduces angiotensinⅡ mediated free radical production in vascular smooth muscle cells:involvement of angiotensin ATl receptor expression and Racl GTPase[J]. Mol Pharmacol, 2001, 59(3): 646-654.
|
